Ed Kaye preps a surprising exit from Sarepta, spurring chatter about a possible sale
Only seven months after Ed Kaye won the right to drop “interim” from the CEO title at Sarepta $SRPT, he’s now planning his exit.
In a surprise move for even the most hard-bitten company observers — who have seen the revolving door outside the CEO’s office turn before — Kaye announced during Thursday’s quarterly call with analysts that he’ll be leaving, in the meantime focusing on “the next series of key initiatives for Sarepta. These key initiatives include approval of Exondys in Europe, the advancement of our next-generation PPMO chemistry into the clinic. And finally, next-generation therapies for DMD such as gene therapy.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.